Delivery Order SPE2DB22D2009-SPE2DB24FL8KC
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order (SPE2DB23FV37R) worth $8,215.42 for the supply of Dupixent 300 mg/2 ml pens. The contract is funded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of September 19, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $13,307.83 for the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. The award is associated with Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order with a Firm Fixed Price of $10,434.52 for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medication. The contract, awarded by the Defense Logistics Agency (DLA), has an ultimate completion date of April 29, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $26,542.08 for the supply of Dupixent 200 mg/1.14 ml syringes. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This...
- This federal contract award to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) is for the delivery of Dupixent 300 mg/2 ml pens, a specialty pharmaceutical product. The $7,691.83 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of February 28, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The award, with a ceiling value of $5,005.47, is for the delivery of Dupixent 300 mg/2 ml pen, a pharmaceutical product. The contract has an ultimate completion date of April 29, 2024 and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,304.72 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract has a ceiling value of $3,304.72 and a completion date of November 7, 2022. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $7,732.96 for the pharmaceutical product Dupixent 300 mg/2 ml Pen 2 ml. The contract was awarded by the Defense Logistics Agency (DLA), a component of the Department of Defense, and has an ultimate completion date of April 25, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
- This federal contract award to Amerisourcebergen Drug Corp., a subsidiary of Cencora, Inc., is a Delivery Order valued at $21,154.15 for the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of March 2, 2023. The award is not designated as a set-aside contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,917.67 for the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of January 30, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB24FL8KCDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $22,405.65 for the supply of Dupixent 300 mg/2 ml pens. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of February 28, 2024. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as a primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.4k | 2/27/24 |